evobrutinib

This page shows the latest evobrutinib news and features for those working in and with pharma, biotech and healthcare.

Merck takes evobrutinib for MS into phase 3, on mixed data

Merck KGaA is putting its BTK inhibitor evobrutinib to the test in two phase 3 multiple sclerosis (MS) trials, the first drug in the class to reach that stage for the ... The new trials – dubbed EVOLUTION RMS 1 and 2 – will compare twice-daily oral

Latest news

New data backs Merck’s segue into MS with BTK inhibitor

Patients had fewer lesions on evobrutinib than placebo. BTK inhibitors are already establishing themselves as important new drugs in cancer, but Merck KGaA has the first data suggesting they could also ... That mechanism also forms the basis of Merck’s
Lilly drops Hanmi-partnered arthritis drug

Merck KGaA is among the front-runners among companies developing BTK inhibitors for inflammatory diseases, with its evobrutinib progressing to phase IIb testing in rheumatoid arthritis last September, while Bristol-Myers

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company

Empowering Strategic Performance Ltd

OUR GOAL: To help clients Metamorph™ Science into Action that changes healthcare to improve the lives of patients. Empowering Strategic...

Latest intelligence

Could formulary intelligence be your brand differentiator?: Proprietary research, and the COVID-19 experience, shows how formulary intelligence can drive competitive advantage at launch...
How COVID-19 is accelerating the threat of antimicrobial resistance: Why antimicrobial resistance needs to be addressed with the same urgency as COVID-19...
Improve clinical trials through patient journey mapping: Could patient journey mapping be your solution to improving clinical study recruitment and retention? While awareness of clinical studies is low across the population, it’s not the only issue. It’s...